证券代码：601567 证券简称：三星医疗 公告编号：临 2024-114 宁波三星医疗电气股份有限公司 关于经营合同预中标的提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）及下属全资子公司宁波三星 智能电气有限公司（以下简称"三星智能"）于近日在国家电网有限公司 2024 年第八 十一批采购（营销项目第三次计量设备招标采购）和 2024 年第八十二批采购（营销 项目第二次充换电设备协议库存招标采购）项目中被推荐为中标候选人，预计合计中 标总金额约为 22,986.55 万元，现将预中标情况公告如下： 本次中标公示媒体是国家电网有限公司电子商务平台，招标人是国家电网有限公 司，其他详细内容请查看国家电网有限公司电子商务平台： https://ecp.sgcc.com.cn/ecp2.0/portal/#/doc/doci-win/2411262465753182_2018060501171 107 2、2024年第八十二批采购（营销项目第二次充换电设备协议库存招标采购） 国 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-113 ● 对外担保逾期的累计金额：无 一、担保情况概述 （一）担保基本情况 ● 被担保人名称：宁波奥克斯智能科技股份有限公司（以下简称"奥克斯 智能科技"） ● 本次担保金额及已实际为其担保的余额 公司预计对子公司提供担保额度不超过 953,350 万元，其中为奥克斯智能科 技提供 400,000 万元担保额度。截至本公告披露日，公司已实际为奥克斯智能科 技提供的担保金额为 338,260 万元（含本次担保）。 ● 本次是否有反担保：无 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 宁波三星医疗电气股份有限公司（以下简称"公司"）于近日与中国民生银 行股份有限公司宁波分行（以下简称"民生银行"）签订了《最高额保证合同》， 就民生银行向奥克斯智能科技提供的授信额度提供连带责任保证。担保的最高债 权本金额为 50,000 万元人民币，担保期间为债务履行期限届满日起三年。 （二）履行的 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown impressive performance in the smart meter sector with significant growth in overseas orders [2] - The company reported a revenue of 10.434 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 25.14%, and a net profit attributable to shareholders of 1.816 billion yuan, up 21.91% year-on-year [2] - The company’s rehabilitation medical services and smart power distribution businesses are driving growth, with expectations of revenue reaching 14.475 billion yuan in 2024, 18.192 billion yuan in 2025, and 22.517 billion yuan in 2026 [2][4] Financial Performance Summary - For Q3 2024, the company achieved a revenue of 3.436 billion yuan, a year-on-year increase of 23.21%, and a net profit of 666 million yuan, up 7.43% year-on-year [2] - The gross profit margin for the first three quarters of 2024 was 36.21%, an increase of 2.59 percentage points year-on-year [2] - The company’s total orders on hand reached 15.620 billion yuan, a year-on-year increase of 35.18%, with domestic orders at 9.374 billion yuan and overseas orders at 6.246 billion yuan, reflecting a growth of 35.10% and 35.30% respectively [2] Financial Forecasts - The company is projected to achieve revenues of 11.463 billion yuan in 2023, 14.475 billion yuan in 2024, 18.192 billion yuan in 2025, and 22.517 billion yuan in 2026 [4] - The net profit attributable to shareholders is expected to be 1.904 billion yuan in 2023, 2.295 billion yuan in 2024, 2.752 billion yuan in 2025, and 3.293 billion yuan in 2026 [4] - The gross margin is forecasted to improve from 34.0% in 2023 to 36.9% in 2026 [4]

宁波三星医疗电气股份有限公司（以下简称"公司"）中标吉尔吉斯斯坦能源部 现代化与可持续发展项目（采购具有 MDMS 功能的商业电能计量自动化系统 （ASCME/AMI）的计量装置），合同金额总计 1,405.89 万美元，约合 1.02 亿人民 币。具体情况如下： 证券代码：601567 证券简称：三星医疗 公告编号：临 2024-112 宁波三星医疗电气股份有限公司 关于子公司签订海外经营合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、交易概述 公司中标吉尔吉斯斯坦能源部现代化与可持续发展项目（采购具有 MDMS 功能 的商业电能计量自动化系统（ASCME/AMI）的计量装置），公司作为供应商，中标 AMI 智能电表总包项目（产品包括智能电表、集中器、IT 设备、系统及运维服务）， 合同金额总计 1,405.89 万美元，约合 1.02 亿人民币。 二、合同对方当事人情况 公司名称：吉尔吉斯斯坦能源部 注册时间：2012 年 5 月 10 日 主营业务：能源监管 是否与公司存在关联关系：公 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-111 宁波三星医疗电气股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ● 被担保人名称：宁波三星智能电气有限公司（以下简称"三星智能"） ● 本次担保金额及已实际为其担保的余额 公司预计对子公司提供担保额度不超过 953,350 万元，其中为三星智能提供 200,000 万元担保额度。截至本公告披露日，公司已实际为三星智能提供的担保 金额为 144,934.46 万元（含本次担保）。 一、担保情况概述 （一）担保基本情况 宁波三星医疗电气股份有限公司（以下简称"公司"）于近日向渣打银行（中 国）有限公司（以下简称"渣打银行"）出具了《最高额保证》，就渣打银行向 三星智能提供的授信额度提供连带责任保证。担保的担保债务余额总额不超过 23,000 万元人民币，保证期间为保证签署之日始直至主协议或及同业拆借下担保 债务发生期间内提取使用的所有融资中最晚到期应付的一笔融资的应付日（不因 提前到期而调整 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2024-110 宁波三星医疗电气股份有限公司 关于子公司签订海外经营合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 宁波三星医疗电气股份有限公司（以下简称"公司"）全资子公司 Nansen Instrumentos de Precisao LTDA.（以下简称"巴西南森"）中标巴西 ENEL 智能电表招 标项目，合同金额总计 1.68 亿巴西雷亚尔，约合 2.07 亿人民币。具体情况如下： 一、交易概述 公司全资子公司巴西南森中标 ENEL 智能电表项目，巴西南森作为供应商，提 供智能电表产品，合同金额总计 1.68 亿巴西雷亚尔，约合 2.07 亿人民币。 二、合同对方当事人情况 公司名称：ELETROPAULO METROPOLITANA ELETRICIDADE DE SAO PAULO S.A. 注册时间：1999 年 合同类型：海外经营合同 项目名称：巴西 ENEL 智能电表招标项目 合同金额：总计 1.68 亿巴西雷亚尔，约 ...

证券代码：601567 证券简称：三星医疗 宁波三星医疗电气股份有限公司 | --- | --- | --- | |-----------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has demonstrated significant cost reduction and efficiency improvements, leading to a continuous increase in gross margin, which reached 36.21% in the first three quarters of 2024, an increase of 2.59 percentage points year-on-year [1] - The smart power distribution segment has seen a revenue growth of 26.54% year-on-year, driven by technological innovations and cost-cutting measures, while the medical services segment has also expanded [1] - The company is positioned as a leading player in the smart power distribution sector, benefiting from both domestic and international demand growth, as well as expansion in its medical services segment [1][2] Financial Performance Summary - For the first three quarters of 2024, the company achieved a revenue of 10.434 billion yuan, a year-on-year increase of 25.14%, and a net profit attributable to shareholders of 1.816 billion yuan, up 21.91% year-on-year [1] - The revenue for Q3 2024 was 3.436 billion yuan, reflecting a year-on-year growth of 23.21%, with a net profit of 666 million yuan, an increase of 7.43% year-on-year [1] - The company’s total orders on hand reached 14.894 billion yuan, a year-on-year increase of 25.74% [1] Earnings Forecast - The company is expected to achieve net profits of 2.307 billion yuan, 2.842 billion yuan, and 3.506 billion yuan for the years 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 19.4, 15.8, and 12.8 [2][3] - The projected revenue growth rates for the years 2024, 2025, and 2026 are 25.2%, 23.6%, and 23.0% respectively [2][4] Comparable Company Valuation - The company’s current valuation is considered reasonable when compared to peers such as Haixing Electric, Huaming Equipment, and Juhua Technology [1][2] - The average P/E ratio for comparable companies is 17.3 for 2024E, while the company’s P/E ratio is 19.4 [3]

Investment Rating - The report maintains an "Outperform the Market" rating for the company [6][15]. Core Views - The company achieved a record high in backlog orders, with total orders reaching 156.20 billion yuan, a year-on-year increase of 35.18%. This includes domestic orders of 93.74 billion yuan (up 35.10%) and overseas orders of 62.46 billion yuan (up 35.30%). Notably, overseas distribution orders surged by 272.51% to 9.62 billion yuan, accounting for 15% of total overseas orders [3][14]. - The company reported a revenue of 104.34 billion yuan for the first three quarters, representing a year-on-year growth of 25.14%. The net profit attributable to shareholders was 18.16 billion yuan, up 21.91% year-on-year, with a non-recurring net profit of 17.48 billion yuan, reflecting a growth of 31.32% [7][12]. - The company is positioned as a leader in the domestic distribution transformer market, with its subsidiary, Ningbo Aokex, holding the top market share in both power grid sectors. The report anticipates a favorable investment cycle in the distribution network driven by multiple factors, including policy support for network upgrades and rural grid transformations [2][14]. Financial Summary - For the third quarter, the company achieved a revenue of 34.36 billion yuan, a year-on-year increase of 23.21%. The net profit attributable to shareholders was 6.66 billion yuan, up 7.43% year-on-year, while the non-recurring net profit reached 6.70 billion yuan, reflecting a growth of 30.03% [7][12]. - The gross profit margin for the third quarter was 39.48%, an increase of 0.89 percentage points year-on-year, while the net profit margin was 19.46%, down 2.98 percentage points year-on-year [12][16]. - The company forecasts net profits for 2024, 2025, and 2026 to be 23.21 billion yuan, 28.76 billion yuan, and 35.65 billion yuan, respectively, with corresponding price-to-earnings ratios of 19, 16, and 13 times [4][15].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][3] Core Views - The company, Samsung Medical (601567), reported a revenue of 10.4 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 25%. The net profit attributable to shareholders was 1.82 billion yuan, up 22% year-on-year, while the net profit excluding non-recurring items was 1.75 billion yuan, reflecting a 31% increase year-on-year [3] - The company's sales gross margin improved to 36.2%, an increase of 2.6 percentage points year-on-year, although the net profit margin decreased by 0.5 percentage points to 17.5% due to high base effects from non-recurring income in the same period last year [3] - The company has a strong order backlog of 15.6 billion yuan as of September 2024, with a year-on-year increase of 35%. The overseas distribution segment is expected to contribute significantly to growth, with overseas orders reaching 6.2 billion yuan, a remarkable increase of 273% year-on-year [3] Summary by Sections Financial Performance - For Q3 2024, the company achieved a revenue of 3.44 billion yuan, a year-on-year increase of 23% but a quarter-on-quarter decrease of 14%. The net profit for Q3 was 670 million yuan, up 7% year-on-year but down 15% quarter-on-quarter [3] - The company forecasts revenues of 14.6 billion, 17.9 billion, and 21.3 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 27%, 23%, and 19%. The net profit attributable to shareholders is expected to be 2.36 billion, 3.01 billion, and 3.66 billion yuan for the same years, with growth rates of 24%, 27%, and 22% [3][6] Market Position - Samsung Medical is positioned as a leading company in the electric meter export market, with continuous breakthroughs in its distribution business [3] - The current stock price is 31.80 yuan, with a market capitalization of approximately 44.87 billion yuan [3]